CEO Eric Ostertag, M.D., Ph.D., oversees Poseida’s first allogeneic CAR-T for B cell maturation antigen, P-BCMA-ALLO1.

CEO Eric Ostertag, M.D., Ph.D., oversees Poseida’s first allogeneic CAR-T for B cell maturation antigen, P-BCMA-ALLO1.

The San Diego-based clinical-stage biopharmaceutical company Poseida Therapeutics has closed its July 10 initial public offering on the Nasdaq Global Select Market (NASDAQ: PSTX), selling 14 million common stock shares for $224 million, increasing its valuation from 10 million shares at $14 a share to $16 a share...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to SDBJ.com archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • San Diego 500 — influential business leaders you need to know
Yours for only $99